具有里程碑意义的系列:局部高级直肠癌的新辅助疗法
Zachary Bunjo1,2, Tarik Sammour3,4
1Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, Australia.
Annals of surgical oncology
|April 22, 2025
概括
对局部晚期直肠癌 (LARC) 的治疗已经发展. 总的新辅助疗法提供了更好的结果和器官保存,标志着直肠癌管理的重大进展.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠道瘤学 胃肠道瘤学
背景情况:
- 局部晚期直肠癌 (LARC) 的治疗已取得显著进展.
- 新辅助性放射疗法与全腹膜切除改善了局部区域控制.
- 最近的试验已经将重点转向LARC的全新辅助疗法 (TNT).
研究的目的:
- 审查LARC中新辅助疗法的演变.
- 突出指导当前LARC治疗的关键研究.
- 讨论个性化治疗选择,包括器官保存,以及未来的研究方向.
主要方法:
- 对LARC管理中的关键临床试验和证据的审查.
- 对治疗模式的分析,从新辅助化学放射疗法到TNT.
- 综合了关于瘤反应,生存结果和器官保存率的数据.
主要成果:
- 与标准的新辅助疗法相比,总的新辅助疗法证明了瘤反应和生存结果的改善.
- 器官保存对于精选的LARC患者来说越来越可行.
- 证据支持基于个体患者和瘤特征的个性化治疗策略.
结论:
- LARC治疗的格局发生了变化,TNT成为一个关键战略.
- 个性化方法正在提高治疗效率和患者的生活质量.
- 目前正在进行的研究继续完善LARC的新辅助剂策略.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
117
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
117
01:29Drugs for Treatment of Ulcerative Colitis in IBD
104
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
104
01:21Inflammatory Bowel Disease V: Surgical Management
65
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
65
01:21Drugs for Treatment of Constipation-Predominant IBS
109
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
109
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
151
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
151